AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, Japan; Collaborative Chairs Emerging and Reemerging Infectious Diseases, National Center for Global Health and Medicine, Graduate School of Medicine, Tohoku University, 1-1, Seriryo-tyo, Aoba-ku, Sendai, Miyagi, Japan.
Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5, Nakauchi-machi, Misasagi, Yamashina-ku, Kyoto-shi, Kyoto, Japan.
J Infect Chemother. 2020 Feb;26(2):211-215. doi: 10.1016/j.jiac.2019.08.013. Epub 2019 Sep 19.
In Japan, hospitals' pharmaceutical affairs committees freely select the drugs to be purchased depending on the regulations of each hospital. This system poses a risk of the absence of essential drugs or an excess of similar drugs, and may promote inappropriate use of third-generation cephalosporins (3GCs) and quinolones. Against this backdrop, we researched availability of antibacterial agents in Japanese hospitals. We conducted a questionnaire-based study in eastern Shizuoka Prefecture, Japan. Questionnaires were sent to 33 hospitals that had established an interactive regional partnership on infection control. We analyzed the number of available oral cephalosporins, macrolides, and quinolones in each hospital, and the correlation between the number of total available antibacterial agents and the hospital scale and cephalexin availability. Thirty-one hospitals participated in this study. First-generation cephalosporin (1 GC) was available in only 22.5% of them. In all participating hospitals, 3GCs were available, with more than one 3 GC available in 74.2%. Quinolones were available in all hospitals, and more than one quinolone in 67.7%. The numbers of hospital beds and total available antibacterial agents were positively correlated and hospitals that owned cephalexin available also significantly more often owned other available antibacterial agents. 1 GC were available in only a few hospitals, while multiple 3GCs and quinolones were available in most. This situation may lead to excess use of 3GCs or quinolones in Japan. A low number of available drugs was associated with cephalexin unavailability. Outpatient antimicrobial stewardship may focus not only on the quality of medicine, but also on the prescribing environment.
在日本,医院的药剂事务委员会根据每家医院的规定自由选择采购的药品。这种制度存在缺乏基本药物或类似药物过多的风险,并且可能会促进第三代头孢菌素(3GCs)和喹诺酮类药物的不当使用。有鉴于此,我们研究了日本医院中抗菌药物的供应情况。我们在日本静冈县东部进行了一项基于问卷调查的研究。我们向 33 家已建立感染控制互动区域合作关系的医院发送了问卷。我们分析了每家医院可提供的口服头孢菌素、大环内酯类和喹诺酮类药物的数量,以及总抗菌药物数量与医院规模和头孢氨苄供应之间的相关性。有 31 家医院参与了这项研究。第一代头孢菌素(1GC)仅在其中 22.5%的医院中可用。所有参与医院均提供 3GC,其中 74.2%的医院提供一种以上 3GC。喹诺酮类药物在所有医院均可提供,其中 67.7%的医院提供一种以上喹诺酮类药物。医院床位数量和总抗菌药物数量呈正相关,且拥有头孢氨苄的医院也更有可能拥有其他可提供的抗菌药物。只有少数医院提供 1GC,而大多数医院提供多种 3GC 和喹诺酮类药物。这种情况可能导致日本 3GC 或喹诺酮类药物的过度使用。可提供的药物数量较少与头孢氨苄不可用有关。门诊抗菌药物管理不仅应关注药物质量,还应关注处方环境。